Telemedicine companies are facing a regulatory shift that many entrepreneurs say would undercut their ability to quickly prescribe medication that helps prevent opioid overdoses.
During the Covid-19 pandemic, telehealth companies benefited from a waiver of the requirement that patients be seen in-person before receiving a telemedicine prescription for buprenorphine, a controlled substance used to treat opioid addiction.
The…
This post first appeared on wsj.com
